Features
Pricing
Events
Reg.News
Short Interest
Explore Content
- Explore
  - Providers
    
    Providers
    
    Free/Commissioned
    
    High Net Worth Offering
    
    Institutional Offering
    
    Free/Commissioned
    
    Research that is free to access for all investors. Companies commission these providers to write research about them.
    View Research
    
    What is our Main Bundle Offering?
    
    Brokers who write research on their corporate clients and make it available through our main bundle offering.
    View Research
    
    What is Institutional?
    
    Research that is paid for directly by asset managers. Only accessible to institutional investors permissioned for access.
    View Research
  - Regions
    
    Regions
    
    UK
    
    Rest of EMEA
    
    N America
    
    APAC
    
    LatAm
  - Exchanges
    
    Exchanges
    
    Aquis Apex
    
    Australian Securities Exchange
    
    Canadian Securities Exchange
    
    Euronext Paris
    
    London Stock Exchange (domestic)
    
    SIX Swiss Exchange
  - Sectors
    
    Sector Coverage
    
    Building & Construction
    
    Discretionary Personal Goods
    
    Discretionary Retail
    
    Energy
    
    Health
    
    Investment Trusts
    
    Media
    
    Resources
    
    Technology
  - Small / Large Cap
    
    Small / Large Cap
    
    UK100
    
    UK250
    
    UK Smallcap
    
    UK Other Main Markets
    
    Other
Login
Sign Up

LIVE

Event in Progress:

Join Here ×

29 May 2025

KDST + NLSP Combined Core Investment Case 29052025

CRISPR Therapeutics AG (CRSP:NYSE), 0 | CRISPR Therapeutics AG (CRSP:NAS), 0 | DEXCOM (DXCM:NYSE), 0 | DexCom, Inc. (DXCM:NAS), 0 | Eli Lilly and Co (LLY:NYSE), 0 | Eli Lilly and Company (LLY:NYS), 0 | Hims & Hers Health, Inc. Class A (HIMS:NYS), 0 | INSULET (PODD:NYSE), 0 | Insulet Corporation (PODD:NAS), 0 | Kadimastem Ltd. (KDST:TAE), 0 | Medtronic plc. Ordinary Shares (MDT:NYSE), 0 | Medtronic Plc (MDT:NYS), 0 | NLS Pharmaceutics Ltd. (NLSP:NAS), 0 | Oramed Pharmaceuticals Incorporated (ORMP:TAE), 0 | Sana Biotechnology, Inc. (SANA:NAS), 0 | Sanofi (SAN:EPA), 0 | Sanofi SA (SAN:PAR), 0 | Senseonics Holdings Inc (SENS:NYSE), 0 | Senseonics Holdings, Inc. (SENS:ASE), 0 | Tandem Diabetes Care Inc (TNDM:NYSE), 0 | Tandem Diabetes Care, Inc. (TNDM:NAS), 0 | Teladoc (TDOC:NYSE), 0 | Teladoc Health, Inc. (TDOC:NYS), 0 | Tiziana Life Sciences Ltd. (TLSA:NAS), 0 | VERTEX PHARMACEUTICALS (VRTX:NYSE), 0 | Vertex Pharmaceuticals Incorporated (VRTX:NAS), 0

- Research Team ACF
- 15 pages

We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM). We provide an investment case analysis and a selection of merged metrics prior to any synergies. The merger creates a cross-platform pre-revenue biotech with lead programs including a proprietary stem-differentiation platform capable of delivering scalable therapies for replacing lost or damaged cells; IsletRx could revolutionize insulin production for Type 1 diabetes (T1D) patients; AstroRx® targets neurod ....

Sign up to access

Get access to our full offering from over 30 providers

Get access to our full offering from over 30 providers

Already a member? Log in here

KDST + NLSP Combined Core Investment Case 29052025

CRISPR Therapeutics AG (CRSP:NYSE), 0 | CRISPR Therapeutics AG (CRSP:NAS), 0 | DEXCOM (DXCM:NYSE), 0 | DexCom, Inc. (DXCM:NAS), 0 | Eli Lilly and Co (LLY:NYSE), 0 | Eli Lilly and Company (LLY:NYS), 0 | Hims & Hers Health, Inc. Class A (HIMS:NYS), 0 | INSULET (PODD:NYSE), 0 | Insulet Corporation (PODD:NAS), 0 | Kadimastem Ltd. (KDST:TAE), 0 | Medtronic plc. Ordinary Shares (MDT:NYSE), 0 | Medtronic Plc (MDT:NYS), 0 | NLS Pharmaceutics Ltd. (NLSP:NAS), 0 | Oramed Pharmaceuticals Incorporated (ORMP:TAE), 0 | Sana Biotechnology, Inc. (SANA:NAS), 0 | Sanofi (SAN:EPA), 0 | Sanofi SA (SAN:PAR), 0 | Senseonics Holdings Inc (SENS:NYSE), 0 | Senseonics Holdings, Inc. (SENS:ASE), 0 | Tandem Diabetes Care Inc (TNDM:NYSE), 0 | Tandem Diabetes Care, Inc. (TNDM:NAS), 0 | Teladoc (TDOC:NYSE), 0 | Teladoc Health, Inc. (TDOC:NYS), 0 | Tiziana Life Sciences Ltd. (TLSA:NAS), 0 | VERTEX PHARMACEUTICALS (VRTX:NYSE), 0 | Vertex Pharmaceuticals Incorporated (VRTX:NAS), 0

Published: 29 May 2025
Author: Research Team ACF
Pages: 15

We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM). We provide an investment case analysis and a selection of merged metrics prior to any synergies. The merger creates a cross-platform pre-revenue biotech with lead programs including a proprietary stem-differentiation platform capable of delivering scalable therapies for replacing lost or damaged cells; IsletRx could revolutionize insulin production for Type 1 diabetes (T1D) patients; AstroRx® targets neurod ....

More Content

More Content

ORMP: Upcoming Expected Milestones Include OraTech Spin-Off & IPO, Launch of Phase 3 Trial

Companies: ORAMED PHARMACEUTICALS (ORMP:NYSE)Oramed Pharmaceuticals Incorporated (ORMP:NAS)

Healthcare - Rebate reform could be just what the doctor ordered

Companies: 0QLRRHO5NNORSANOGSKAZN

Attractive Eli Lilly (LLY) Credit Profile

Companies: Eli Lilly and Company

Nothing new – strong Genzyme but weak diabetes and fledgling Praluent

Companies: Sanofi SA

ACF Thematic Research Regenerative Medicine Diabetes Treatment & Innovation 13032025

Companies: LLY SENS CRSP VRTX PODD SAN LLY DXCM TNDM DXCM TDOC MDT TDOC VRTX CRSP KDST MDT SENS NLSP ORMP SAN PODD TLSA HIMS SANA TNDM

Research Tree

Useful Links

Features
Pricing
RNS/Newswires Feeds
Providers Hub
Company Hub
Stock Pick League
Chrome Extension
iOS and Android Apps

Account

Login
Join Now
Contact

Follow us on Linkedin
Follow us on X

© Research Tree 2025

Terms of Service
Privacy Policy and Statement on Cookies

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Top

Home
Features
Pricing
Event Hub
Reg.News
Short Interest Tracker
Explore Content
Providers
Contact
Sign Up
Sign In